// App-Quantinova.ai

POS1403 (2022) : CLINICAL CHARACTERISTICS, HEALTH CARE RESOURCE UTILIZATION, AND COSTS ASSOCIATED WITH FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN GERMANY

Researchers

Presenter

  • B. Ding

Principal Investigators

  • M. Pignot

  • E. Garal-Pantaler

  • B. Villinger

  • B. Desta

  • K. Schmidt

  • S. Golam

  • H. Stirnadel-Farrant

  • A. Schwarting

Medical Centers

  • AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden

  • ZEG Berlin GmbH, Center of Epidemiology and Health Research Berlin, Berlin, Germany

  • Team Gesundheit GmbH, Health Economics Department, Essen, Germany

  • AstraZeneca, BioPharmaceuticals Medical, Nürnberg, Germany

  • AstraZeneca, BioPharmaceuticals Medical, Nürnberg, Germany

  • AstraZeneca Pharmaceuticals, Cambridge, United Kingdom

  • University Medicine of Johannes Gutenberg University Mainz, Rheumatology and Clinical Immunology, Mainz, Germany

Locations

  • Sweden

  • Germany

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved